Metallic nanoparticles esetabilized with carbosilane dendrones and their uses (Machine-translation b

专利摘要:
Metallic nanoparticles stabilized with carbosilane dendrons and their uses. The invention relates to metallic nanoparticles, preferably gold and silver, stabilized with dendrons, of carbosilane structure and functionalized in their periphery with anionic or cationic groups, which give the nanoparticle a net negative or positive charge, respectively. These nanoparticles have been synthesized by reducing a metal precursor in the presence of dendritic wedges or by replacing ligands already present in metal nanoparticles with carbosilane dendrons. In addition, the invention relates to its method of obtaining and its uses in biomedicine. (Machine-translation by Google Translate, not legally binding)
公开号:ES2609464A1
申请号:ES201500669
申请日:2015-09-16
公开日:2017-04-20
发明作者:Francisco Javier DE LA MATA；Rafael Gómez Ramírez；Javier Sánchez-Nieves Fernández；Cornelia E. PEÑA GONZÁLEZ；José Luis COPA PATIÑO；Juan Soliveri De Carranza；Jorge PÉREZ SERRANO；M. Angeles MUÑOZ FERNÁNDEZ；Jose Luis JIMÉNEZ FUENTES；Pilar GARCÍA BRONCANO
申请人:Universidad de Alcala de Henares UAH；Fundacion para la Investigacion Biomedica del Hospital Gregorio Marañon；
IPC主号:

专利说明:

antiseptic sprayers and antimicrobial coatings, being present even in tissues with bactericidal properties (http: // www. nanotechproject. org / cpi /).
Gold and silver metallic NPs are usually stabilized with ligands that contain a thioether function that binds directly to the metal surface, while the additional function would be found at the other end of the molecule. Other functions used in stabilization can be amines and phosphines. The synthesis of NPs (Au and Ag) with active functions is carried out following two main protocols, although in both the reduction of the metal precursors is carried out. In the first one, the reduction with a reducing agent is carried out in the presence of stabilizing ligands such as citrate or thiolalkanes (these NPs are commercial), and then these stabilizing ligands are replaced by those of interest. In the second, the reduction of the precursor is carried out in the presence of the ligand of interest. In this way, the process is simplified.
One type of molecule that has recently been used to stabilize NP, and which also has a specific attraction for biomedical applications, are dendritic molecules (GR Newkome, C. D Shreiner. Polymer 2008, 49, 1; JMJ Fréchet, DA Tomalia. Dendrimers and Other Dendritic Polymers VCH, Weinheim 2002). The dendritic molecules, dendrimers and dendrons, are hyperbranched molecules of arborescent construction, of well-defined size and three-dimensional structure and that have uniform chemical properties due in part to their low polydispersity as a consequence of their controlled synthesis. Dendrimers have a spherical molecular topology, mainly in older generations, while dendrons have a cone or wedge topology. In both cases, there is a surface that contains the active groups of these molecules. In addition, in the case of dendrons, they have an additional position called a focal point, which can be used to introduce a new active function or as an anchor to other systems, such as NPs. As previously mentioned, the presence of a thiol group at said focal point would be of interest for the functionalization of these NPs.
Both dendrimers (E. Boisselier, D. Astruc. Chem. Soco Rev. 2009, 38, 1759) and dendrons (TJ Cho, RA Zangmeister, R. 1. MacCuspie, AK Patri, and VA Hackley. Chem. Mat. 2011, 23, 2665) have been used to stabilize metallic NPs by
the periphery or focal point groups. The main functions present to achieve stabilization are thiol, amino or phosphine groups
Dendrimers and dendrons themselves can have biological activity, thus acting as antibacterial, antiviral or antiprionic agents, for example. They can also act as transport agents for nucleic acids or drugs. This activity depends mainly on the peripheral functions, and seems to be related to the multivalence that dendrimers have, which allows the presence of a large number of functionalities on the same molecule, and its nanoscopic size. The dendritic molecules described in the literature and potentially useful as antiviral agents have on their periphery some of the following functions: carbohydrates, peptides and anions.
On the other hand, dendrimers and dendrons with cationic groups are used as transporters of nucleic acids in therapies against HIV, cancer, etc., through the formation of nanoconjugates called dendriplexes; or they have microbicidal properties.
As regards the transport of drugs, the nature of the latter (cationic or anionic) determines in some way the type of dendrimer to be used when looking for an electrostatic interaction. However, if a covalent binding of the drug is performed, the presence of additional cationic or anionic groups will serve to favor the solubility of the drug or generate synergies with the activity of the ionic groups of the dendritic molecule.
Another aspect to consider in the formation of dendritic molecules is their internal structure. Different dendritic skeletons have been described, among which is the carbosilane skeleton, characterized by the presence of very stable C-C and Si-C bonds, of low polarity. With this type of skeleton, carbosilane dendritic molecules of both cationic and anionic nature have been prepared (W02011 / 1 01520
A2).
The former have shown their ability to interact with oligonucleotides or small interfering RNAs and transport them to the interior of the cells, so
they can be considered as non-viral vectors for the transfection of nucleic material into several types of cell lines in gene therapy processes (N. Weber, P. Ortega, M. 1. Clemente, D. Shcharbin, M. 8ryszewska, FJ de la Mata, R. Gómez, MA Muñoz-Fernández, J. Control, Re / eased, 2008, 132, 55). These systems are even capable of overcoming the blood brain barrier. Also, cationic carbosilane dendrimers and dendrons have antimicrobial activity both against Gram positive bacteria and against Gram negative bacteria (8. Rasines, JM Hernández-Ros, N. de las Cuevas, JL Copa-Patiño, J. Soliveri, MA Muñoz- Fernández, R. Gómez, FJ de la Mata. Da / ton Transactions, 2009, 40, 8704; ES2265291). In addition, cationic carbosilane dendritic molecules did not generate resistance in the bacteria treated with them.
As for anionic carbosilane systems, the presence of carboxylate, sulphonate and sulfate groups in them has given them a very important activity against HIV. The importance of its antiviral ability is because it prevents infection of epithelial cells and also reduces infection in already infected cells.
The synthetic process of carbosilane systems uses various approaches. To obtain cationic systems, allylamine hydrosilylation reactions (eg C3HsNH2, C3HsNMe2) have been used with dendrimers and dendrons with Si-H terminal bonds and subsequent quaternization, for example with HCI and Mel. Dendrimer alcoholysis reactions with Si-CI bonds have also been used, although in this case unstable dendrimers are obtained in a humid atmosphere. Finally, the thiol-ene addition of thiols that support ammonium groups has been more recently documented, allowing to obtain cationic dendrimers and dendrons more easily. On the other hand, to obtain anionic carbosilane dendrimers, Michael-type additions of methyl acrylate or vinyl sulphonate have been made on systems with terminal functions -NH2. Also for this type of systems, the thiol-eno addition of thiols that support ester or sulphonate groups makes it easier to reach dendrimers or dendrons with anionic groups or their precursors.
DESCRIPTION OF THE INVENTION
The present invention provides metal nanoparticles (NP) coated with dendrons of carbosilane structure that are functionalized on their periphery with anionic groups (such as carboxylate, sulphonate or sulfate), which give the macromolecule a negative net charge, or cationic (ammonium), that give the dendrimer a positive net charge. Preferably, the nanoparticles are gold and silver and the carbosilane dendrons have been functionalized by thiol-eno addition.
The method of obtaining the NPs of the invention allows, through a simple process, the synthesis of cationic or anionic systems, and also the possibility of synthesizing heterofunctionalized NPs, which also consist of introducing some dendron with one or more of its branches replaced by different groups, such as chromophores groups. In addition the invention provides its uses in biomedicine.
Therefore, a first aspect of the present invention relates to an NP (hereinafter compound of the invention) comprising:
- A nucleus composed of metallic atoms, mainly gold or silver atoms, of nanoscopic size. This nucleus can have an arrangement of its spherical, cylindrical, prism or other atoms, with at least one dimension between 1 and 1000 nm.
- The metal surface of the nanoparticle is coated with a dendritic compound. By "dendritic compound" refers in the present invention to a highly branched macromolecule where the growth units, branches or branches have carbosilane skeleton. This dendritic compound is preferably a dendron, also called the latter as a dendritic wedge that refers to a highly branched cone-shaped macromolecule that is defined by a focal point, the units, branches
or growth branches, which start from said focal point and the outer layer, surface or periphery of said branches that incorporates functional groups. In addition, through the focal point it is linked to the metal surface of the nanoparticle.
The focal point can be selected from the group - (CH2) z-R1; where: z is an integer that varies from 1 to 10, preferably z varies from 1 to 5 and more preferably z is 4; and R1 is a group selected from the list preferably comprising a group of type -SR2, -NH2; where R2 may preferably be H, C (O) Me, or any of its salts.
The outer layer of the dendrimer or dendron consists, totally or partially, of units 5 equal or different from the group of formula (1):
where: R3 is a (C1-C4) alkyl group, preferably R3 is a methyl group; p is an integer and varies between 1 and 3, preferably pes 2; and 10 R4 is the following group - (CH2) x-S- (CH2) and -R5; x represents an integer that varies from 2 to 5; preferably x is 2 or 3; and represents an integer that varies from 1 to 10; preferably and varies between 1 and 5; R5
15 is a group -OH, -S03H, -OS03H, -COOR 'or -NR "R"', where R ', R "and R"', independently represent a (C1-C4) alkyl group or a hydrogen; or any of its salts.
When R5 is -NR "R '' ', preferably R" and R' '', they represent independently
A (C1-C4) alkyl or hydrogen group, more preferably a (C1-C2) alkyl or hydrogen group, even more preferably R5 is a -N group (CH3h or a -NH2 group. Even more preferably x is 2 and still more preferably and is 2. In a more preferred embodiment, when R5 is -NR "R" ', R4 is the group - (CH2h-S- (CH2kN (CH3) 2 or - (CH2h-S (CH2h-NH2.
When R5 is a group -C02R ', or any of its salts, preferably R' is H or CH3, more preferably x is 2 or 3, and even more preferably and is 1 or 2.
When R5 is a group -S03H or -OS03H, or any of its salts, preferably x is
30 2 or 3, and more preferably and is 2 or 3.
The term "alkyl" refers in the present invention to aliphatic, linear or branched chains, having 1 to 4 carbon atoms, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, tert- butyl or sec-butyl, preferably has 1 to 2 carbon atoms, more preferably the alkyl group is a methyl.
The compound of the present invention can also be cationic, forming ammonium groups (for example -NH3 + or -NMe3 +), that is, when RS is an amino, or anionic group, forming the carboxylate, sulfate or sulphonate groups, for the rest of RS groups described above.
Therefore, the present invention not only includes the compounds themselves, but any of their salts, for example, alkali metal or alkaline earth metal salts, for example they can be selected from sodium, potassium or calcium salts. Preferably the salts are sodium or halogen salts, which can be selected from chloride, bromide, iodide salts; or triflate. Preferably the salts are iodide and chloride.
In another preferred embodiment, the compound of the invention further comprises, in the external layer, at least one functional group RS '(RS' = OR6, NHR6, C02R6) of different nature to the rest of the R5 groups that are part of said external layer . These R6 groups can be selected from a tag molecule, a leader group or an active ingredient.
The term "tag molecule" refers in this description to any biorecognizable substance, chromophore, fluorophore or any other group detectable by spectrophotometric, fluorometric, optical microscopy, fluorescence or confocal, antibody and / or NMR techniques, and which easily allows detection of another molecule that alone is difficult to detect and / or quantify. For example, and without limitation, the fluorophore is selected from a list comprising cytochrome, fluorescein, rhodamine and dansyl.
By "director group" is meant a molecule or functional group capable of directing the dendritic compound specifically to a type of cells or to a specific area of a cell, for example but not limited to folic acid, mannose groups, a signal peptide or an antibody, among others known to any person skilled in the art. Said lead group can be previously functionalized to bind the dendritic compound.
By "active ingredient" or "drug" is meant in the present invention any purified chemical substance used in the prevention, diagnosis, treatment, mitigation or cure of a disease; to avoid the appearance of an unwanted physiological process; or to modify physiological conditions for specific purposes. Preferably, said active ingredient is capable of binding to an amine or containing an amino group by which it binds to the dendritic compound, or is capable of binding to the dendritic compound by the functional groups it contains or with a prior functionalization, for example, but not limited to penicillin, or where the active substance is capable of binding to an alkyne group through azide groups, for example AZT (zidovudine).
In a preferred embodiment, the NP is dendronized with a dendron of first, second, third, fourth or successive generations. The term "generation" refers to the number of iterative branches that are necessary for the preparation of the compound.
Another aspect of the present invention relates to the process for obtaining the compounds of the invention, which comprises a reduction reaction of the metal precursor in the presence of the carbosilane dendron having a thiol group at the focal point or the like, or the replacement of stabilizing ligands already present in the metallic NPs by the respective carbosilane dendrons.
Also the dendritic compound used for the synthesis can correspond to a dendrimer with a nucleus of the type - (CH2) zSS- (CH2) z-, where z is an integer that varies from 1 to 10, preferably z varies from 1 to 5 and more preferably z is 4; and a periphery as described for dendrons in the present invention.
In a preferred embodiment of the process of the invention, the reaction is carried out in the presence of a polar solvent, preferably water, and a reducing agent, preferably NaBH4. Also, the invention can be carried out by substitution from NPs having thiolates on their surface, performing this process in a mixture of H20ltoluene solvents or other organic solvents not miscible with water.
Thus, for example, anionic NPs can be synthesized with terminal groups as per
example carboxylate, sulphonate, sulfate; or, from NPs with anionic precursor groups such as esters or carboxylic acid that after their introduction to the compound are transformed into the corresponding anion by treatment with a base, such as NaOH, KOH, K2C03 or others that comply with it. function. The compounds of the invention obtained are stable and soluble in water in their ionic forms and also
5 manage to isolate with good yields. The synthesis of these ionic and neutral dendronized NPs can be represented, in general, by scheme 1, direct method, or by scheme 2, indirect or exchange method:
M @ (SGnCx (F) o) 10 Scheme 1. Synthesis of NPs by the direct method. [MX] = [AuCI4] -, AgN03. i) reducing agent; M = Au, Ag.
15 Scheme 2. Synthesis of NPs by exchange.
Where: The metal nanoparticles are represented as M @ (SGnCx (F) o), being preferably formed by gold and silver metal atoms. M @ indicates the nature of the nanoparticle, being M Au or Ag, while entering
20 parentheses indicate the NP stabilizing ligand. Anionic, cationic or neutral dendrons are represented as XGnCx (F) or, where: n indicates the number of generation G.
X, indicates the nature of the focal point; X = SH for derivatives with a function uncle !.Cx, indicates the length of the carbon chain between the atom of Si and S.example, when we start from the compound XGnVo (V = vinyl), Cx is C2, or whenWe start from XGnAo (A = allyl), Cx is C3 and so on. The compoundsXGnVo and XGnAo of the following examples are described in: J. SánchezNieves, P. Ortega, M. A. Muñoz-Fernandez, R. Gómez, F. J. de la Mata.Tetrahedron 2010, 66, 9203; A. W. van der Made, P.W. N. M van Leeuwen. J.Chem. Soc., Chem. Commun. 1992,1400; E. Fuentes-Paniagua, C. E. PeñaGonzález, M. Galán, R. Gómez, F. J. de la Mata, J. Sánchez-Nieves.Organometallics 2013, 1789.F, indicates the nature of the functional groups) located on the periphery of thedendrimer (R5 = C02 ', S03 ", OS03", S03H, OS03H, C02Me, C02H, OH, NH3 +,NMe2W, NMe3 +, NH2, NMe2) and "o" the number of these functional groups, which goesto depend on the number of generations.S-R corresponds to a stabilizing ligand described in the literature,mainly with R = alkyl or alkyl chain carboxylic acid.
On the other hand, obtaining cationic compounds with terminal ammonium groups, for example NMe3 +, can be produced by a quaternization reaction of the corresponding amino group using an RX derivative, dialkyl sulfates (C1-CS), methyl triflate, or any of its combinations as a quaternizing agent (where R is selected from hydrogen, (C1-C24) alkyl, alcohol (C1-C24) or an aryl, preferably benzyl; and X is a halogen, preferably CI, Sr or 1), as for example methyl iodide (Mel), HCI, methyl chloride, methyl bromide, ethyl chloride, ethyl bromide, propyl chloride, hexyl chloride, dodecyl chloride, benzyl chloride, benzyl bromide, ethanol bromide , ethanol iodide (HO-CH2CH2-1) or any combination thereof. Also, in the case of compounds functionalized with ammonium groups of the NR2 'HCI type, they are neutralized with basic medium and subsequently can be quaternized with other alkylating agents such as those described above. The synthesis of these cationic or neutral dendronized NPs can be represented, in general, by scheme 1, direct method, or by scheme 2, indirect method
or exchange.
The present invention also relates to the biomedicine uses of the dendronized NPs described above which have cationic or anionic terminal groups. These include the use of cationic derivatives as non-viral transport agents for the transfection or internalization of nucleic material inside different cell lines in gene therapy processes or also the use of these cationic or anionic compounds as therapeutic agents "per se ", for example as antibacterial, antiviral or antiprionic agents.
In addition, said NPs can be heterofunctional, with the advantage of being able to perform more than one function simultaneously. Thus, for example, anionic NPs, in addition to having antiviral capacity due to their negative charge, may be marked to facilitate their monitoring or may also have lead groups that direct dendrimers specifically towards their place of action. In the same way, heterofunctional cationic NPs can simultaneously have, for example, positive charges for the transport of nucleic acids or anionic drugs and leader groups such as an antibody to direct these dendrimers to a specific location, or also fluorophores or other drugs.
In another preferred embodiment the compounds of the invention, mainly cationic ones, are used as antimicrobial agents. Therefore, they can be used for the prevention and / or treatment of bacterial infections.
Also the compounds of the invention, mainly the anionic ones, exhibit antiviral activity. Because of this, they can be used for the prevention and / or treatment of diseases of viral origin, such as AIDS, Herpes, Influenza or others.
Taking into account the biocidal activity of the compounds of the invention, another aspect of the present invention relates to the use of these compounds as biocidal agents for non-therapeutic applications, such as, but not limited to, preventing the occurrence of microorganisms in surfaces or water treatment.
Another aspect of the present invention relates to the use of the compounds of the invention, both cationic and anionic, for the preparation of a medicament. More preferably, the medicament is used for the prevention and / or treatment of diseases caused by microorganisms, such as viruses, bacteria, protozoa or fungi. More preferably prevention and / or treatment are for diseases caused by HIV or bacterial infections.
Another aspect of the present invention relates to a pharmaceutical composition comprising at least one dendronized NP as described above and a pharmaceutically acceptable carrier. In addition, this pharmaceutical composition may comprise another active ingredient, preferably an antibiotic, antiviral or anti-inflammatory. The antibiotic may be from the group of beta-lactams, such as penicillin, or others such as erythromycin. The anti-inflammatory may be for example ibuprofen and the antiviral AZT.
The "pharmaceutically acceptable vehicles" that can be used in said compositions are the vehicles known to a person skilled in the art. Examples of pharmaceutical preparations include any solid composition (tablets, pills, capsules, granules, etc.) or liquid (gels, solutions, suspensions or emulsions) for oral, nasal, topical or parenteral administration. For anionic compounds, preferably the administration will be topical and even more preferably in the form of a gel. In the case of cationics, preferably the administration will be oral, parenteral (injectable), or topical.
In another aspect, the present invention relates to a method of treatment or prevention of diseases caused by microorganisms, such as viruses, bacteria, protozoa or fungi in a mammal, preferably a human, comprising the administration of a therapeutically effective amount of a composition comprising at least one dendritic compound of the invention. Preferably, the administration of the composition can be performed orally, nasally, topically or parenterally. For anionic compounds, preferably the administration will be topical and even more preferably in the form of a gel. In the case of cationics, preferably the administration will be oral, parenteral (injectable) or topical.
In the sense used in this description, the term "therapeutically effective amount" refers to the amount of the composition calculated to produce the desired effect and, in general, will be determined, among other causes, by the characteristics
typical of the composition, age, condition and history of the patient, the severity of the disease, and the route and frequency of administration.
Another aspect of the present invention relates to the use of the cationic compounds of the invention as a non-viral vector. Preferably, the vector is used for transfection.
or internalization of nucleic material in gene therapy processes, that is, the compounds of the invention can act as transfection agents in gene therapy.
By "nucleic material" refers in the present invention to a material, isolated and / or purified, which comprises a nucleotide sequence and can be selected from oligonucleotides, siRNA or AON.
Another aspect of the present invention relates to the use of the non-viral vector of the invention, for the preparation of a medicament. More preferably, for the preparation of a medicament for the treatment of HIV infection or cancer in gene therapy.
The possibility of synthesis and easy manipulation of these compounds and the possibility of adding to this type of metallic NPs ligands that allow their address to a specific place of action, is a great advantage over other vectors used in gene therapy.
The greatest advantage of the complexes, NP / nucleic material formulated in the present invention, is that they have a uniform and flexible structure allowing the possibility of versatilely modifying the skeleton and the surface thereof. In addition, the direct dendronization of the NP allows to estimate the molecular weight and the number of charges of these systems.
It is also possible to use the compounds of the invention as vehicles for transporting molecules, preferably molecules with pharmacological activity (active ingredients), and more preferably anionic or cationic molecules, depending on whether the compound is cationic or anionic respectively, the active substance can be an antibiotic, an anti-inflammatory or an antiviral, including for example and not limited to an antibiotic from the beta-lactam group, such as penicillin, to a
anti-inflammatory such as ibuprofen or an antiviral such as AZT.
Throughout the description and the claims the word "comprises" and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and features of the invention will be derived partly from the description and partly from the practice of the invention. The following examples and figures are provided by way of illustration, and are not intended to be limiting of the present invention.
DESCRIPTION OF THE FIGURES
Figure 1. TEM image (left) and distribution histogram (right) of the Au @ NPs (G2C2 (NMe2) 4) obtained by the direct method (average size = 1.88 nm (469 nanoparticles measured with the Image J program)).
Figure 2. 1 H-NMR (020) of Au @ (G1C2 (NMe31) 2) obtained by the direct method.
Figure 3. TEM image (left) and distribution histogram (right) of the Au @ NPs (G1C2 (NMe31) 2) obtained by the direct method (average size = 1.80 nm (14975 nanoparticles measured with the Image J program)).
Figure 4. 1 H-NMR (020) of Au @ (G1C2 (NMe3CI) 2) obtained by the direct method.
Figure 5. TEM image (left) and distribution histogram (right) of the Au @ NPs (G1C2 (NMe3CI) 2) obtained by the direct method (average size = 1.80 nm (14975 nanoparticles measured with the Image J program)).
Figure 6. 1 H-NMR (020) of Au @ (G2C2 (NMe3IM (SR) (R = (CH2) 11Me) obtained by the exchange method.
Figure 7. TEM image (left) Au @ (G2C2 (NMe31) 4) (SR) (R = (CH2) 11Me) of the NPs obtained by the exchange method.
Figure 8. 1 H-NMR (020) of Ag @ (G1C2 (NMe3CI) 2) obtained by the direct method. fifteen
Figure 9. TEM image (left) and distribution histogram (right) of the Ag @ NPs (G1C2 (NMe3CI) 2) obtained by the direct method (average size = 1.67 ± 3.82 nm (2315 nanoparticles measured with the Image J program) )
Figure 10. 1 H-NMR (020) of Au @ (G1C2 (S03Na) 2) obtained by the direct method.
Figure 11. TEM image (left) and distribution histogram (right) of the Au @ NPs (G1C2 (S03Nah) obtained by the direct method (average size = 2.4 nm (1974 nanoparticles measured with the Image J program)).
Figure 12. 1 H-NMR (020) of Au @ (G1C2 (S03Nah) (SR) (R = (CH2) 11Me) obtained by the exchange method.
Figure 13. TEM image (left) Au @ (G1C2 (S03Na) 2) (SR) (R = (CH2) 11Me) of the NPs obtained by the exchange method (average size = 1.2 nm (19874 nanoparticles measured with the program Image J program)).
Figure 14. 1 H-NMR (020) of Au @ (G2C2 (C02Me) 4) obtained by the direct method.
Figure 15. TEM image (left) and distribution histogram (right) of the Au @ NPs (G2C2 (C02Me) 4) obtained by the direct method (average size = 1.5 nm (556 nanoparticles measured with the Image J program)).
Figure 16. 1 H-NMR (020) of Au @ (G2C2 (C02Me) 4) (SR) (R = (CH2) 11Me) obtained by the exchange method.
Figure 17. TEM image (left) Au @ (G2C2 (C02Me) 4) (SR) (R = (CH2) 11Me) of the NPs obtained by the exchange method (average size = 1.4 nm (3699 nanoparticles measured with the program) Image J)).
Figure 18. 1 H-NMR (020) of Au @ (G1C2 (C02NaM obtained by the direct method.
Figure 19. TEM image (left) and distribution histogram (right) of the Au @ NPs (G1C2 (C02Na) 2) obtained by the direct method (average size = 2.0 nm (2957 16 nanoparticles measured with the Image J program)) .
Figure 20. Bactericidal activity of cationic NPs M @ (GnC2 (NMe3CI) m) (M = Au, Ag; n = 1.2, 3; m = 2.4.8) in mg / L of NP.
Figure 21. Viability of CMSPs treated with anionic gold nanoparticles by MTT. The CMSP were treated with the anionic gold nanoparticles for 48 hours using concentrations of 100, 50, 10 and 1. Jg / ml, showing, after the incubation time, and after performing an MTT test, a viability greater than 80 % in all concentrations. NT, untreated control; DMSO (10%), positive control of cell death; Dext (Dextran 10¡JM), negative control of cell death. Both controls and concentrations were studied in triplicate.
Figure 22. Viability of TZM.bl treated with anionic gold nanoparticles by MTT. TO). TZM.bl cells were treated with concentrations of 1.0.5.0.1.0.05,
0.01¡Jg / ml of Au @ nanoparticles (GnC2 (S03Na) m) (SR) (BDCP071-073) for 48 hours, after incubation time, and after performing a MTT test, the maximum concentration at which The viability exceeded 80%, it was 0.05¡Jg / ml. B). TZM.bl cells were treated with the Au @ nanoparticles (GnC2 (S03Na) m) (BDCP062-064) at concentrations of 100, 50, 10, 1, 0.5, 0.1, 0.05 Y0.01 ¡. Jg / ml for 48 hours, after the incubation time, and after performing an MTT test, the maximum concentration at which the viability exceeded 80%, was 10¡Jg / ml, 0.1¡Jg / ml and 0.5¡Jg / ml, respectively. NT, untreated control; DMSO (10%), positive control of cell death; Dext (Dextran 10¡JM), negative control of cell death. Both controls and concentrations were studied in triplicate.
Figure 23. Pre-treatment and infection of TZM.bl with R5-HIV1NLAD8 and X4-HIV-1NL4.3 viral isolates. 15,000 TZM.bl / well cells were plated in a 96-well plate and pre-treated with the different anionic gold nanoparticles at the previously selected non-toxic concentrations, for 1 hour. Next, the infection of the cells with a concentration of 20ng / 106 cells of the viral isolates was carried out. After 3 hours of infection, the cells were washed with PBS and left in culture medium for 72 hours. After the post-infection time
determined the percentage of infection by measuring the luminescence using a reader of
plates.
Figure 24. Pre-treatment and infection of CMSP. 200,000 cells were plated! well in a 96-well plate and pre-treated with the nanoparticles at concentrations of 100 IJg / ml for 1 hour. Next, infection was performed with 50 ng / 106 cells of the R5-HIV-1NLAD8 isolate for 3 hours. After the time of infection, the cells were washed with PBS and left in culture medium for 72 hours. After the post-infection time, the percentage of infection was determined by quantification of the p24gag antigen by ELlSA.
EXAMPLES
Example 1.-Nanoparticles functionalized with cationic groups
The structures of some dendronized NPs are added, which are representative for the rest of the systems described in the following examples.
Synthesis of Au @ (G2C2 (NMe2) 4). To a aqueous solution of HAuCI4 (8.82 mL, 0.26 mmol, 29.5 mM) was added a solution of tetraoctylammonium bromide in toluene (21.2 mL, 1.06 mmol, 50 mM). The mixture was stirred until all the color had been transferred from the aqueous phase to the organic phase. To the above mixture was added a toluene solution of the dendron HSG2C2 (NMe2) 4 (0.26 mmol), followed by dropwise addition and with rapid stirring of a fresh aqueous solution of NaBH4 (6.25 mL, 1.30 mmol, 208 mM ). At the end of the addition, the mixture was kept under stirring for another 4 hours. The nanoparticles precipitated from the solution and turned out to be insoluble in different organic solvents (THF, ether, tOluene), and partially soluble in DMSO. Data for Au @ (G2C2 (NMe2) 4): Average gold core diameter (TEM): D = 1.88 nm. SPR (UV-visible): 538.1 nm.
Synthesis of Au @ (G1C2 (NMe3Ih).To an aqueous solution of HAuCI4 (15 mL, 0.45 mmol, 30 mM) was added dropwise
5 an aqueous solution of the dendron HSG1C2 (NMe3Ih (40 mL, 0.5 mmol, 12.5 mM). Then, a fresh aqueous solution of NaBH4 (12.5 mL, 2.5 mmol, 200 mM) was added dropwise and with strong stirring. In addition, the mixture was kept under stirring for 4 hours.The nanoparticles were purified by dialysis (MWCO 10,000) to obtain Au @ (G1C2 (NMe31h) (114 mg, stored in MiLiQ water at 4
10 OC). Data for Au @ (G1C2 (NMe3Ih): NMR (D20): 1H NMR: or -0.09 (SiCH3), 0.61 (SCH2CH2CH2CH2Si), 0.91 (SiCH2CH2S), 1.36 (SCH2CH2CH2CH2Si), 2.70 (SiCH2CH2S),
2.95 (SCH2CH2N), 3.13 (NCH3), 3.53 (SCH2CH2N). Au / (I) reagent molar ratio = 1: 1. Anal. Ob .: C, 23.34; H, 4,741; N, 2,721; S, 8.014. TGA: Au, 51.11; (1), 48.89. Molar Ratio Cale Au / (I) = 3.72: 1 in the nanoparticle. SPR (UV-visible): 545.1 nm. Zeta potential:
15 +46.1. DLS (Z-average d.nm) = 4.91 nm. Average diameter of the gold core (TEM): D = 3.72 nm. NAu = 1590; Calculation of dendrons attached to the surface Nd = 442. Approximate molecular weight calculation: AU1s9o (C19H4sbN2S3Si) 442. Average M = 612900.87 gmol-1.
Synthesis of Au @ (G1 C2 (NMe3CI) 2). Following the procedure described for Au @ (G1C2 (NMe3Ih), AU (SG1 (NMe3CI) 2) was obtained from the reaction of HAuCI4 (30 mL, 0.9 mmol, 30 mM) with the compound HSG1C2 (NMe3CI) 2 (80 mL, 1 mmol, 12.5 mM) .and NaBH4 (25 mL, 5 mmol, 200 mM).
25 nanoparticles were purified by dialysis (MWCO 10,000) to obtain AU (SG1 (NMe3CI) 2) (273 mg, stored in MiLiQ water at 4 oC). Data for AU (SG1 (NMe3CI) 2): NMR (D20): 1H NMR: or -0.07 (SiCH3), 0.60 (SCH2CH2CH2CH2Si),
0.91 (SiCH2CH2S), 1.41 (SCH2CH2CH2CH2Si), 1.70 (SCH2CH2CH2CH2Si), 2.70 (SiCH2CH2S), 2.97 (SCH2CH2N), 3.10 (NCH3), 3.51 (SCH2CH2N). Au / (I) molar ratio of
5 reagents = 1: 1. TGA: Au, 54.80; (1), 45.20. SPR (UV-visible): 528.1 nm. Zeta potential: +54.1. DLS (Z-average d.nm) = 13.81 nm. Average diameter of the gold core (TEM): D = 1.80 nm. NAu = 180; Calculation of dendrons attached to the surface Nd = 59. Calculation of approximate molecular weight: AU159o (C19H45CbN2S3Si) 442. Average M = 64761.64 gmol-1.
10 Synthesis of Au @ (G2C2 (NMe31) 4) (SR) (R = (CH2) 11Me). To a solution of functional nanoparticles hoisted with Au dodecathiolate (SC12) (50 mg) in dichloromethane CH2Cb (25 mL) was added an aqueous solution of HSG2 (NMe31) 4 (187 mg, 0.143 mmol, 25 mL of MiLiQ water) under argon. The mixture was stirred at
15 room temperature until the exchange ended (the exchange of the ligand can be easily observed, by transferring the color from the organic phase to the aqueous phase). At the end of the exchange reaction, the phases were separated and the aqueous phase was washed with CH2Cb (2 x 5 mL). Then, the aqueous phase was concentrated in vacuo (5 mL) and purified by dialysis, obtaining Au @ (G2C2 (NMe31) 4) (SR)
20 (134 mg, stored in MiLiQ water at 4 oC). Data for Au @ (G2C2 (NMe31) 4) (SR): NMR (D20): 1H NMR (D20): Ó -0.07 (SiCH3) 0.05 (SiCH3), 0.54 (SCH2CH2CH2CH2Si, SiCH2CH2CH2Si) 0.87 (SCH2 (CH2) 9CH3 SiCH2CH2S), 1.31 (SCH2 (CH2) 9CH3, SCH2CH2CH2CH2Si, SiCH2CH2CH2Si), 1.61 (SCH2CH2CH2CH2Si), 2.65 (SiCH2CH2S),
2.92 (SCH2CH2N), 3.32 (NCH3), 3.61 (SCH2CH2N). SPR (UV-visible): 541.9 nm.
Synthesis of Ag @ (G1C2 (NMe3CI) 2).To an aqueous solution of AgN03 (16.3 mL, 0.49 mmol, 30 mM) was added dropwise
5 a solution of compound HSG1 (NMe3Clh (43.2 mL, 0.54 mmol, 12.5 mM). Next, a freshly prepared aqueous solution of NaBH4 (13.5 mL, 2.7 mmol, 200 mM) was added dropwise and with strong stirring. In addition, the mixture was kept under stirring for an additional 4 hours.The nanoparticles were purified by dialysis (MWCO 10,000) to obtain Ag (SG1 (NMe3Clh) (108 mg, stored in water
10 MiLiQ at 4 oC). Data for Ag (SG1 (NMe3CI) 2): NMR (D20): 1H NMR: ~ -0.06 (SiCH3),
0.59 (SCH2CH2CH2CH2Si), 0.91 (SiCH2CH2S), 1.41 (SCH2CH2CH2CH2Si), 1.79 (SCH2CH2CH2CH2Si), 2.71 (SiCH2CH2S), 2.97 (SCH2CH2N), 3.10 (NCH3), 3.51 (SCH2CH2N). Au / (I) reagent molar ratio = 1: 1. TGA: Au, 46.46; (1), 53.54. Molar ratio calc. Au / (I) = 3.99: 1 in the nanoparticle. SPR (UV-visible): 447.8 nm. Zeta potential:
15 +54.2. DLS (Z-average d.nm) = 17.54 nm. Average diameter of the gold core (TEM): D = 1.67 nm. NAu = 521; Calculation of dendrons attached to the surface Nd = 131. Calculation of approximate molecular weight: AU521 (C19H45CbN2S3Si) 131. Average M = 56200.27 gmol-1.
Example 2.-Nanoparticles functionalized with anionic groups.
The structures of some dendronized NPs are added, which are representative for the rest of the systems described in the following examples.
Synthesis of Au @ (G1C2 (S03NaM.Following the procedure described for Au @ (G1C2 (NMe31) 2), Au @ (G1C2 (S03Na) 2) isobtained from the reaction of HAuCI4 (10 mL, 0.3 mmol, 30 mM) with the compoundHSG1C2 (S03Nah (26.6 mL, 0.3 mmol, 12.5 mM) and NaBH4 (7.5 mL, 1.5 mmol, 200 mM).
5 The nanoparticles were purified by dialysis (MWCO 10,000) to obtain Au @ (G1C2 (S03Nah) (200 mg, stored in MiLiQ water at 4 OC). Data for Au @ (G1C2 (S03Na) 2): NMR (020): 1H NMR: 5 0.06 (SiCH3), 0.61 (SCH2CH2CH2CH2Si),
0.89 (SiCH2CH2S), 1.93 (SCH2CH2CH2S), 2.60 (SiCH2CH ~, SCH2CH2CH2S), 2.90 (SCH2CH2CH2S). Au / (I) reagent molar ratio = 1: 1. Anal. Ob .: C, 21.36; H, 4.12; S,
10 18.17. TGA: Au, 48.06; (1), 51.89. Molar Ratio Cale Au / (I) = 2.54: 1 in the nanoparticle. SPR (UV-visible): 549.7 nm. Zeta potential: -28.8. DLS (Z-average d.nm) = 33.66 nm. Average diameter of the gold core (TEM): O = 2.4 nm. NAu = 427; Calculation of dendrons attached to the surface Nd = 168. Calculation of approximate molecular weight AU427 (C15H31 Na206S5Si) 168. Average M = 175124.32 gmol-1.
. s ~ S03Na)
S ~ Yes.F
~~
S ~ S03Na
Synthesis of Au @ (G1C2 (S03Na) 2) (SR) (R = (CH2h1Me).Following the procedure described for Au @ (G2C2 (NMe31) 4) (SR),Au @ (G1C2 (S03Nah) (SR) was obtained from the Au reaction (SC12) (10 mg, 5 mL) and
20 HSG1C2 (S03Nah (129 mg, 0.239 mmol, 5 mL of MiLiQ water), obtaining Au @ (G1C2 (S03Na) 2) (SR) (127 mg, stored in MiLiQ water at 4 OC). Data for Au @ (G1C2 (S03Nah) (SR): NMR (D20): 1H NMR (020): 1H NMR: 5 -0.01 (m, SiCH3), 0.54 (m, SCH2CH2CH2CH2Si), 0.85 (SCH2 (CH2) gCH3, SiCH2CH2S), 1.37 ( m, SCH2 (CH2) gCH3, SCH2CH2CH2CH 2Si), 1.59 (m, SCH2CH2CH2CH2 Si), 1.92 (m, SCH2 CH2CH2S), 2.58 (m,
25 SiCH2CH2S, SCH2CH2CH2S, SCH2CH2CH2CH2Si), 2.89 (m, SCH2CH2CH2S) SPR (UVvisible): 540.7 nm. Zeta potential: -57.0. Average diameter of the gold core (TEM): O = 1.2 nm.
Synthesis of Au @ (G2C2 (C02Me) 4).Following the procedure described for Au @ (G2C2 (NMe2) 4), Au @ (G2C2 (C02MeM seobtained from the reaction of HAuCI4 (15 mL, 0.5 mmol, 30 mM), tetraoctylammonium bromide(40 mL, 2 mmol, 50 mM), HSG2C2 (C02Me) 4 (0.5 mmol) and NaBH4 (12.5 mL, 2.5 mmol,
5 200 mM). The resulting mixture was concentrated in vacuo (5 mL) and the nanoparticles protected with dodecanothiolate were precipitated with hexane (1,155 g, stored in toluene at 4 OC). Data for Au @ (G2C2 (C02MeM: NMR (CDCb): 1H NMR (CDCb): ~
0.09 (SiCH3), 0.01 (SiCH3), 0.53 (SCH2CH2CH2CH2Si, SiCH2CH2CH2Si), 0.85 (SCH2 (CH2) gCH3, SiCH2CH2S), 1.25 (SCH2 (CH2) gCH3, SCH2CH2CH2CH2Si,
10 SiCH2CH2CH2Si), 1.66 (SCH2CH2CH2CH2Si), 2.64 (SiCH2CH2S), 3.22 (SCH2C02), 3.71 (C02CH3). SPR (UV-visible): 520.8 nm. DLS (Z-average d.nm) = 130.6 nm. Average gold core diameter (TEM): D = 1.5 nm.
15 Synthesis of Au @ (G2C2 (C02MeM (SR) (R = (CH2) 11Me)) Following the procedure described for Au @ (G2C2 (NMe31) 4) (SR), Au @ (G2C2 (C02Me) 4) (SR ) was obtained from the reaction of Au (SC12) (50 mg, 25 mL of CH2Cb) and HSG2C2 (C02Me) 4 (126 mg, 0.143 mmol, 25 mL of CH2CI2) The mixture was stirred at room temperature for 2 days. It was then concentrated in vacuo (5 mL) and the
The residue obtained was washed with hexane (2 x 5 mL), yielding Au @ (G2C2 (C02Me) 4) (SR) (stored in hexane water at 4 oC). Data for Au @ (G1C2 (C02MeM (SR): NMR (D20): 1H NMR (CDCb): ~ -0.08 (SiCH3), 0.02 (SiCH3), 0.54 (SCH2CH2CH2CH2Si, SiCH2CH2CH2Si), 0.85 (SCH2 (CH2) gCH3, SiCH2CH2S), 1.24 (SCH2 (CH2) 9CH3, SCH2CH2CH2CH2Si, SiCH2CH2CH2Si), 1.61 (SCH2CH2CH2CH2Si), 2.65 (SiCH2CH2S),
25 3.23 (SCH2C02), 3.72 (C02CH3). SPR (UV-visible): 526.6 nm. Average gold core diameter (TEM): D = 1.4 nm.
Synthesis of Au @ (G1C2 (C02Nah).Following the procedure described for Au @ (G1C2 (NMe31) 2), Au @ (G1C2 (C02Na) 2) is
5 obtained from the reaction of HAuCI4 (30 mL, 0.9 mmol, 30 mM), HSG1C2 (C02Na) 2 (80 mL, 05 mmol, 12.5 mM) and NaBH4 (25 mL, 5 mmol, 200 mM). The nanoparticles were purified by dialysis (MWCO 10,000) to obtain AU (SG1 (C02Na) 2) (169.7 mg, stored in MiLiQ water at 4 oC). Data for AU (SG1 (C02Na) 2): NMR (D20): 1H NMR: Ó -0.09 (SiCH3), 0.53 (SCH2CH2CH2CH2Si), 0.82 (SiCH2CH2S), 1.17 (SCH2CH2CH2CH2Si,
10 SCH2CH2CH2CH2Si), 2.53 (SiCH2CH2S), 3.09 (SCH2C02Na). SPR (UV-visible): 521.3 nm. Zeta potential: -32.4. DLS (Z-average d.nm) = 36.90 nm. Average gold core diameter (TEM): D = 2.0 nm.
15 BIOLOGICAL ACTIVITY OF CATIÓN NANOPARTíCULAS AGAINST BACTERIAS.
The antibacterial capacity of cationic NPs against Gram + type bacteria (eg S. aureus) and Gram- (eg E. coll) has been studied. The main difference between these
20 bacteria lies in the constitution of the bacterial membrane. However, its activity against other bacteria and other microorganisms such as amoebas and other parasites is not ruled out.
MATERIALS AND METHODS
Gold nanoparticles 6 nanoparticles functionalized with dendrons of different generation prepared by the direct method of the type M @ (GnC2 (NMe3CI) m) were analyzed, which will now be referred to when M = Au as BDCP078 (n = 1, m = 2), BDCP079 (n = 2, m = 4) and BDCP080 (n = 3, m = 8), functionalized with a first, second and third generation dendron respectively; and when M = Ag as BDCP086 (n = 1, m = 2), BDCP087 (n = 2, m = 4) and BDCP088 (n = 3, m = 8), functionalized with a first, second and third generation dendron respectively.
Assessment of the antibacterial capacity of the compounds. The minimum inhibitory concentration (MIC) of the compounds is determined in 96-well microplates, using the standard ISO 20776-1 method. The test is carried out in sextuplicate for each concentration analyzed. For the tests the bacteria Escherichia coli (CECT 515, Gram negative) and Staphylococcus aureus (CECT, 240 Gram positive) were used. Both strains were obtained in the "Spanish Collection of type crops" (CECT). A stock solution is prepared by dissolving 0.01024 g of the compound under study in 10 ml of distilled water (1024 ppm). After that, sterile distilled water is added until the desired concentrations are obtained. In each well of the microplates, 100 IJL of the solution with the desired concentration are added and it is completed with 100 IJL of MuellerHinton broth (Scharlau, ref. 02-136) double concentrate of what is indicated for its preparation. Finally, 5 IJL of a bacterial solution of 2 x 107 CFU / mL are added. The microplates are incubated at 37 ° C for 24 h using an ELX808iu microplate reader (Bio-Tek Instruments). The minimum bactericidal concentration is the smallest concentration of the compound that does not allow bacterial growth. The minimum bactericidal concentration (CMB) is calculated by inoculating
51J1 of each of the wells of the microplate used for the calculation of MIC, in a
Petri dish with Mueller-Hinton agar (ref. 02-136, Scharlau). After 48 h of incubation at
37 ° C, the presence of colonies is observed. CMB is determined as the concentration
minimum in which the growth of bacteria is not detected.
Assessment of the hemolytic capacity of the compounds.
1.5 mL of a solution of sheep erythrocytes (RBC, Oxoid sheep erythrocytes) are taken and resuspended in 5 mL of saline phosphate buffer (PBS pH 7.4; 137 mM NaCI, 2.7 mM KCI, 10 mM Na2HP04 and 1.8 mM KH2P04). The solution obtained is centrifuged for 15 min at 3,000 rpm. The process is repeated three times to wash the erythrocytes and finally they are resuspended after the last centrifugation in 20 mL of PBS. The solution of the compound to be tested is prepared by dissolving in PBS or in a 0.9% NaCl saline solution at a concentration of 1024 ppm (1024 mg / L). From this stock solution, sterile distilled water is added until the concentration of the desired compound to be tested is obtained.
A mixture consisting of 0.5 mL of the dendrimer solution is made at the desired concentration with 0.5 ml of the prepared erythrocyte solution. Mixing is done in eppendorf tubes. The mixture is kept at 37 ° C for 30 min under gentle stirring. After the time the eppendorf tubes are centrifuged at 1,500 rpm for 5 min. The supernatant is transferred to another eppendorf tube and the absorbance at 412 nm is measured as an index of the hemoglobin released by erythrocyte lysis. As positive control an eppedndorf tube is used in which 0.5 mL of the erythrocyte solution is mixed with 0.5 mL of distilled water and proceed as described above; In this case the hemolysis obtained is 100%. As negative control an eppendorf tube is used in which 0.5 mL of the erythrocyte solution is mixed with 0.5 mL of saline solution, or PBS, without dissolved compound; In this case the degree of hemolysis is 0%.
The percentage of hemolysis is calculated using the following equation: (Problem Absorbance-Negative Control Absorbance / Positive Control Absorbance-Negative Control Absorbance) per 100. In the tests performed, HC20 is obtained, which is the concentration of the compound necessary to produce a 20% hemolysis. The experiments are performed in triplicate.
RESULTS
The cationic NPs object of the invention have antibacterial activity against strains of S. aureus and E. colí (Figure 20). The results show the influence of the type of bacteria, Gram positive or Gram negative, on the activity of the systems studied. The silver NPs have a similar activity in all three generations, although in particular the third generation are more active with S. aureus and the first with E. eoli. However, first-generation gold NPs give much higher values in both types of bacteria than other systems. On the contrary, the second and third generation AuNPs present similar values with each other and with the corresponding silver ones, except for the case mentioned in the third generation silver NPs for S.
aureus
BIOLOGICAL ACTIVITY OF ANIONIC NANOPARTíCULAS AS ANTIVIRAL AGENTS AGAINST HIV. Anionic gold nanoparticles whose functional groups interact with the human immunodeficiency virus (HIV) gp120 protein, the CD4 cell receptor and / or the CCR5 or CXCR4 co-receptors have been studied, acting in the early stages of the viral cycle inhibiting infection by The hiv. The results indicate that these anionic AuNPs could be possible microbicides by stopping HIV infection. However, its activity against other viruses such as influenza or herpes is not ruled out.
MATERIALS AND METHODS
Gold nanoparticles Six functionalized nanoparticles with dendrons of different generation were analyzed. By a direct method of dendronization, 3 gold nanoparticles Au @ (GnC2 (S03Na) m) were obtained, which from now on will be referred to as BDCP062 (n = 1, m = 2), BDCP063 (n = 2, m = 4 ) And BDCP064 (n = 3, m = 8), functionalized with a first, second and third generation dendron respectively. Another 3 gold nanoparticles were synthesized by an indirect method, Au @ (GnC2 (S03Na) m) (SR) ((R = (CH2) 11Me), which will be referred to as BDCP071 (n = 1, m = 2), BDCP072 (n = 2, m = 4) and BDCP073 (n = 3, m = 8), functionalized with a first, second and third generation dendron respectively, which in addition to the anionic dendrons in the nanoparticle maintains dodecanothiol ligands They cannot be totally replaced.
Reagents
Dextran (SigmaAldrich), a complex and branched polysaccharide formed by numerous glucose molecules as a negative control of cellular toxicity and Dimethylsulfoxide (DMSO, SigmaAldrich), was used as controls for cell death. As a control of viral replication inhibition, T-20 (Genetech, San Francisco, Ca, USA), an inhibitor of HIV-1 fusion to target cells was used due to its binding to the gp41 glycoprotein of the virus. Nuclease-free water (Promega) was used to obtain the working dilutions of the compounds from the stock and the PBS (Lance) to wash the plates in the different experiments. The Trypan Blue solution (Sigma-Aldrich) was used to stain the dead peripheral blood mononuclear cells (CMSP), taking advantage of the alteration of their membrane, thus facilitating their counting with the optical microscope. Interleukin 2 (IL-2, Bachem, Switzerland) and phytohemagglutinin (PHA, Remel, Santa Fe, USA), were used to stimulate CMSP of cell cultures.
Cells. Peripheral Blood Mononuc / eares cells (CMSP). Blood samples were obtained from buffycoats from healthy anonymous donors from the transfusion center of the Community of Madrid following the recommendations of current regulations (Royal Decree 1088/2005). The CMSPs were isolated by means of a Ficoll-Hypaque® gradient (Rafer, Spain) following the HIV Biobank standards of the HGU Gregario Marañón (Madrid, Spain). The blood was diluted in a 1: 1 ratio with PBS and centrifuged in density gradient. After said centrifugation, the halo containing the CMSPs was recovered and several cycles of centrifugal washing with PBS (10 minutes at 1500 rpm) were carried out to clean and purify them. The resulting CMSPs were resuspended in RPMI 1640 culture medium (Lite technology, Madrid, Spain) supplemented with 10% heat-inactivated bovine fetal serum (SFB), 2 mM L-glutamine and an antibiotic cocktail (125mg / mL ampicillin , 125 mg / mL chloxacycline and 40 mg / mL gentamicin; Sigma-Aldrich, St-Louis, USA). CMSPs were cultured with 60 IU / mL IL-2 and stimulated with 2 jJg / mL PHA for 48 hours under culture conditions (37 ° C in an atmosphere of 5% C02 and 95% relative humidity).
HEK293T (ATCC), packaging cell line derived from the human renal epithelium. Be
Routinely grow in DMEM culture medium supplemented with 5% SFB 28
Heat inactivated, 2mM L-glutamine and the antibiotic cocktail mentioned above at 37 ° C in an atmosphere of 5% C02.
TZM.bl (ATCC® PTA-5659 ™), a cell line from a HeLa line generated from the JC53-bl line, which expresses the C04, CCR5 and CXCR4 markers, and the luciferase and 3-galactosidase genes under the control of the HIV-1 promoter. They were obtained through the NIH AIOS Research and Reference Reagent Program. They were grown in OMEM culture medium (Life technology, Madrid, Spain) supplemented with 5% heat-inactivated SFB, 2 mM L-glutamine and the antibiotic cocktail mentioned above. at 37 ° C in an atmosphere of 5% CO2.
Isolated viral. Viral isolates R5 tropic VI H-1 NLAD8 and X4 tropic VI H-1 NL43, are laboratory isolates produced by transient transfection of plasmids pNL (A08) and pNL4.3, respectively, from the NIH AIOS Research and Reference Reagent Program , Oivision of AIOS, NIAIO, on the 293T cell line. To do this, plasmids containing the viral genome were grown in E. coli and isolated and purified by the PlasmidMaxiPrep kit, QIAGEN®. Starting from confluent cultures of 293T cells that were transfected with 15 µg of plasmid / plate using a calcium chloride transfection method. At 24 h the medium was removed and the cultures were washed twice to remove the plasmid not integrated into the cell genome. Fresh medium was added to the culture and the viral production present in the culture supernatant was collected at 24 h and 48 h. Viral stocks were clarified by filtration (0.45 µm filter) and viral titration was carried out by quantification of the HIV-p24gag antigen by an enzymatic immunoassay (INNOTESJ® HIV antigenmAb, Innogenetics Nv, lwijndrecht, Belgium), following The manufacturer's instructions. In addition, the infectivity of the viral isolates in the TlM.bl cell line was evaluated, for this purpose 2 x 104 cells were cultured with complete culture medium in 96-well plates and the viral isolates were added at different concentrations for 3 hours, after this time the cells were washed twice with sterile PBS and left in culture medium. After 48 hours post-infection the percentage of infection was determined by the luminescence measurement (Luciferase Assay System, Promega) using a plate reader (Synergy 4 Plate Multilector, Biotek Instrument).
Toxicity test by reduction of tetrazolium salts. This technique is a calorimetric assay based on the selective ability of living cells to reduce 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide in formazan insoluble crystals. This method makes it possible to determine the lethal effect of the compounds under study, in this case the anionic gold nanoparticles, on cell metabolism, since cell damage results in a decrease in the mitochondrial activity of the cell and the cytotoxicity of these can be measured. molecules This test was carried out according to the manufacturer's instructions (MTT, SigmaAldrich, St Louis, USA). Briefly, after incubation time of the different cell populations in 96-well plate (2x104 TZM.bl / well and 2x105 CMSP / well) cells with the different selected concentrations of the anionic gold nanoparticles, the supernatant containing the nanoparticle and was replaced by 200j..lL of Opti-MEM® (serum-free medium or fenal red) and 20 j..IL of MTT (Tiazolyl Blue, 5 mg / mL, final well concentration of 0.5mg MTT / mL) per well. After 3 hours of incubation under culture conditions, the plate was centrifuged at 1500
r.p.m. 10 min and the subsequent removal of the supernatant with excess MTT that did not react. Formazan crystals were dissolved in 200 j..IL of DMSO. The plate was stirred at 700 rpm. to ensure the correct dissolution of said crystals and the concentration of formazan was determined by spectrophotometry using a plate reader (Synergy 4 Plate Multilector, Biotek Instrument) at a wavelength of 570nm (690 nm reference). The spectrophotometer was calibrated to O using Opti-MEM® without cells. The relative cell viability (%) with respect to the control (untreated cells) was calculated based on the formula: [A] test / [A] control x 100. Dextran was used at 10j..lM as a negative control of cell death, due to its harmless effect, while 10% DMSO was used as a positive toxicity control. Each experiment was performed in triplicate.
Inhibition assay of gold nanoparticles: quantification of HIV-1. The ability to inhibit HIV infection of gold nanoparticles in TZM.bl and CMSP was determined. For this, the different cell populations were pre-treated with the different concentrations of non-toxic anionic gold nanoparticles in 96-well plate (2x104 TZM cells.bl / well and / or 2x105 activated CMSP / well) for 1 hour under conditions of culture and subsequently the cells were infected with 20 ng HIV / 106 TZM.bl and 50 ng HIV / 106 CMSP of the different viral isolates for 3 hours. Next, the supernatant containing the nanoparticles and the excess virus was removed, a wash with 200 µL of PBS was performed and replaced with 200 µl of fresh medium, maintaining the cultures for 72 h. After this time post-infection in the TZM.bl cell line, the supernatant was removed, followed by a wash with 200¡J1 of PBS, to proceed to cell lysate by adding 50¡J1 lysis buffer (Promega) per well for 30 min at 4 ° C. Subsequently, they were centrifuged at 1500
r.p.m. for 2 min to precipitate the cell debris, 25 JI of the cell lysate was collected and added to a reading plate to add 100 JI / well of luciferase substrate (Luciferase Assay System, Promega) and the infection percentage was determined by measuring luminescence using a plate reader (Synergy 4 Plate Multilector, Biotek Instrument). For the CMSP at 72 h post-infection, the plates were centrifuged at 1500 rpm. 10 min and the culture supernatants were collected to quantify the production of HIV Ag p24gag by ELlSA. Each experiment was carried out in triplicate.
RESULTS In this study with AuNPs with negative charges we have shown their antiviral activity to prevent HIV infection, as a preventive mechanism of transmission. In this work, six AuNPs have been studied, their biosecurity in CMSP and TZM.bl has been evaluated, as well as their effectiveness in inhibiting the transmission of HIV-1 and viral infection, in order to determine and characterize their potential use as microbicides.
It is described that in the heterosexual transmission of HIV-1, it is mainly the R5 tropism viruses that are dominant and involved in the early stages of infection. However, variants of HIV-1 type X4 have also been found in semen, although their role in these first steps of sexual infection is still unknown. The gold nanoparticles BDCP062, BDCP063, and BDCP064 significantly decreased infection by both R5-HIV and X4-HIV isolates in TZM.bl cells, showing HIV-1 infection inhibition values> 80%. However, the BDCP071 and BDCP072 AuNPs showed an infection inhibition for the R5 viral isolate around 40% and 70% BDCP073 in TZM cells. bl. When the same experiments were performed in a more physiological model such as CMSP, AuNPs BDCP064 and BDCP073 inhibited HIV-1 infection by 78% and 88%, respectively. This data is of great value, since the inhibition is against an R5-HIV viral isolate, which is the majority at the time of sexually transmitted virus, in the acute phase of infection. Cell viability
First, an initial screening of the different nanoparticles was carried out to determine the concentrations at which they did not produce toxicity in CMSP and in the TZM.bl. Toxicity was studied by the MTT assay, based on the ability of living cells to reduce 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide in formazan insoluble crystals. Concentrations with a cell viability> 80% were considered non-toxic.
The cell viability in CMSP of AuNPs was studied using concentrations ranging from 1 to 100 iJg / ml, which were not toxic since a viability> 80% was obtained (Figure 21).
In the TZM cell line. bl were studied concentrations of the range of 1 to 100 iJg / ml obtaining high toxicity values, so a new MTT test was performed with lower concentrations in a range of 0.01 to 1 iJg / ml. Toxicity was variable depending on the type of anionic gold nanoparticle used. For the BDCP071, BDCP072 and BDCP073 AuNPs, concentrations greater than 1 iJg / ml (data not shown) were discarded (Figure 22a), while for the nanoparticles BDCP062, BDCP063 and BDCP064 the full toxicity range of 0.01 to 100 iJg is shown / ml (Figure 22b). Evaluation of antiviral activity.
In order to develop a new strategy for the prevention of HIV-1 infection, we analyzed the percentage of inhibition of HIV infection that occurred when cells were pre-treated with anionic gold nanoparticles, in First place was made in TZM.bl and later in CMSP.
Pre-treatment and infection in TZM. bl
The anionic AuNPs were non-toxic at the concentrations of 10 iJg / ml, 0.1 iJg / ml and 0.5 iJg / ml, for the nanoparticles BDCP062, BDCP063 and BDCP064 respectively (Figure 22B) and 0.05 iJg / ml for BDCP071, BDCP072 and BDCP073 (Figure 22A). Once pretreated the cells were infected with the R5-HIV-1NLAD8 isolate of AuNPs and with the isolate 32
X4-HIV-1 NL4.3 for Au @ (GnC2 (S03Na) m) The results show an inhibition of HIV-1 infection in the case of AuNPs BDCP062, BDCP063, and BDCP064 up to 80% at maximum non-toxic concentration for the tropic R5 viral isolate and almost 100% in the case of BDCP062 and BDCP064 and 50% for BDCP063 for the isolate
5 viral X4. Meanwhile, in the case of BDCP071, BDCP072 and BDCP073 AuNPs, the inhibition was not significant, with 36%, 34% and 64% respectively for the tropic R5 viral isolate (Figure 23).
Pre-treatment and infection in CMSP
10 The maximum non-toxic concentrations that were 100 IJg / ml for all AuNPs were selected as concentrations for pre-treatment in the CMSP. After pre-treatment in the CMSP, they were infected with the R5-HIV-1 NLAD8 isolate. Infection was quantified by the detection of p24gag antigen in the culture supernatant. The results show that BDCP064 and BDCP073 nanoparticles inhibit the
15 HIV-1 infection in CMSP in 78% and 88%, respectively, while in the rest of AuNPs the inhibition was not significant (Figure 24).

权利要求:
Claims (47)
[1]
one. Dendronized metal nanoparticle with carbosilane dendrons that
understands:
5 -A nucleus composed of metal atoms, mainly gold atoms or
silver;
-A dendritic compound covering the metal surface, preferably a
dendron containing a focal point and an outer layer;
-The focal point can be selected from the group - (CH2) z-R1; where z is a number
10 integer that varies from 1 to 10, preferably z varies from 1 to 5 and more preferably z
it is 4; and R1 is a function that preferably comprises a sulfur atom or a
amino group -NH.
-The outer layer or periphery consists, totally or partially, in equal units or
different from the group of formula (1):
fifteen
where: R3 is a (C1-C4) alkyl group,
p is an integer and varies between 1 and 3, and
R4 is the following group - (CH2) x-S- (CH2} and -R5;
twenty x represents an integer that varies from 2 to 5;
and represents an integer that varies from 1 to 10; Y
R5 is a group -OH, -S03H, -OS03H, -COOR ', -NR "R"', where R ', R "Y
R "', independently represent a (C1-C4) alkyl group or a
hydrogen; or any of its salts.
25
[2]
2. The methane nucleus may preferably have an arrangement of its atoms
spherical, cylindrical, prism or others, with at least one dimension between 1 and 1000 nm,
but preferably spherical with a diameter between 1 and 20 nm.
3. A compound according to claim 1, wherein the dendritic compound is a wedge
dendritic or dendrimer.3. 4
[4]
Four. Compound according to any one of claims 1 to 3, wherein said compound is a dendritic wedge with a sulfur atom at the focal point of the type -S (CH2) z-Si; where z is an integer that varies from 1 to 10.
[5]
5. Compound according to any of the preceding claims, wherein p is 2.
[6]
6. Compound according to any of the preceding claims, wherein R3 is a methyl group.
[7]
7. Compound according to any of the preceding claims, wherein x is 2 or 3. R5
[8]
8. Compound according to any of the preceding claims, wherein it is a group -N (CH3h.
[9]
9. Compound according to the preceding claim, wherein y is 2.
[10]
10. Compound according to any one of claims 1 to 4, wherein R5 is a group -C02H 0-C02Me.
[11]
eleven. Compound according to the preceding claim, wherein y is 1 or 2.
[12]
12. Compound according to any one of claims 1 to 4, wherein R5 is a group -S03H or -OS03H.
[13]
13. Compound according to the preceding claim, wherein y is 2 or 3.
[14]
14. Compound according to any of the preceding claims, wherein the outer layer further comprises a group R5 'different from the rest of groups R5 that form the outer layer of the dendritic compound (R5' = OR6, NHR6, C02R6). These R6 groups can be selected from a tag molecule, preferably a fluorophore, a leader group or an active ingredient.
[15]
fifteen. Compound according to the preceding claim, wherein R6 is a fluorophore that is selected from the list comprising fluorescein, rhodamine, dansyl, cyanines.
[16]
16. Compound according to any of the preceding claims, wherein said compound is cationic, when R5 is an ammonium group, or anionic for the rest of R5 groups described in claim 1.
[17]
17. Compounds according to the preceding claim, wherein said compound is in the form of salt.
[18]
18. Process for obtaining the compounds described according to any one of claims 1 to 17, which comprises a reaction between the metal precursor and a dendritic wedge.
[19]
19. Process for obtaining the compounds described according to any one of claims 1 to 17, which comprises a reaction between the metal precursor and a dendrimer with a core of type - (CH2) zSS- (CH2) z-, where z is an integer which varies from 1 to 10, preferably z varies from 1 to 5 and more preferably z is 4; and a periphery as described for dendrons in the present invention.
[20]
twenty. Process for obtaining the compounds described according to any one of claims 1 to 17, wherein the metal precursor is tetrachlorouric acid H [AuCI41 or any of its salts.
[21]
twenty-one. Process for obtaining the compounds described according to any one of claims 1 to 17, wherein the metal precursor is AgN03 or another silver salt.
[22]
22 Process for obtaining the compounds described according to any one of claims 1 to 17, wherein said reaction is preferably carried out in the presence of a polar solvent such as water or an R7-OH alcohol, where R7 is a (C1-C1Q) alkyl group .
[23]
2. 3. Process for obtaining the compounds described according to any one of claims 1 to 17, wherein said reaction is preferably carried out in the presence
[24]
24. Method according to the preceding claim, wherein the reducing agent is
of a reducing agent preferably sodium tetrahydroborate or other boron derivatives, diisobutylaluminum hydride or other aluminum derivatives.
[25]
25. Process for obtaining the compounds described according to any one of claims 1 to 17 wherein the molar ratio in the reaction between the metal precursor and the dendron is n: 1; where n is preferably a value between 0.1 and 20.
[26]
26. Process for obtaining the compounds described according to any of claims 1 to 17, which comprises a reaction between an already formed nanoparticle and a dendritic wedge, which has the characteristics set forth in the preceding claims.
[27]
27. Process for obtaining the compounds described according to any one of claims 1 to 17, which comprises a reaction between an already formed nanoparticle and a dendrimer with a nucleus of the type - (CH2) zSS- (CH2) z-, where z is a number integer that varies from 1 to 10, preferably z varies from 1 to 5 and more preferably z is 4; and a periphery as described for dendrons in the present invention.
[28]
28. Use of the compounds described according to any of claims 1 to 17, as an antibacterial, amebicidal or antiparasitic agent.
[29]
29. Use of the compounds described according to any of claims 1 to 17, as an antiviral agent.
[30]
30 Use according to the preceding claim, wherein the virus is HIV.
[31]
31. Use of the cationic compounds described according to any one of claims 1 to 17, as a non-viral vector.
[32]
32 Use according to the preceding claim, wherein the non-viral vector is used for the transfection or internalization of nucleic material.
[33]
33. Use according to the preceding claim, wherein the nucleic material is selected from oligonucleotides, siRNA or DNA.
[34]
3. 4. Use of the compounds described according to any of claims 1 to 17, for the preparation of a medicament.
[35]
35 Use of the compounds described according to any of claims 1 to 17, for the preparation of a medicament for the prevention and / or treatment of diseases caused by a microorganism.
[36]
36. Use according to the preceding claim, wherein the disease is caused by a bacerial or parasitic infection.
[37]
37. Use of the compounds described according to any one of claims 1 to 17, for the preparation of a medicament for the prevention and / or treatment of diseases caused by HIV.
[38]
38. Pharmaceutical composition comprising a compound according to any one of claims 1 to 17.
[39]
39. Pharmaceutical composition further comprising a pharmaceutically acceptable carrier and / or other active ingredient, preferably an antibiotic, anti-inflammatory or
antiviral
[40]
40 Pharmaceutical composition comprising a compound according to any one of claims 1 to 17 and further comprising nucleic material.
[41]
41. Pharmaceutical composition according to the preceding claim, wherein the nucleic material is selected from oligonucleotides, siRNA or DNA.
[42]
42 Use of the compound according to any of claims 1 to 17, as a vehicle for
transport of molecules
[43]
43 Use according to the preceding claim, wherein the molecule is anionic or cationic. 38
[44]
44. Use according to the preceding claim, wherein the molecule is a drug, preferably an antibiotic.
[45]
Four. Five. Use according to claims 42-43, wherein the molecule is an antiviral drug.
FIG 1
I¡¡
I
'
~~
[3]
3.8 3.6 J. '"] -, JO 2.8 U VI 2.2 2.0 1.8 ppm 1.6 LA l.2 1.0 ( ,, 8 0.6 0: 4 O ~ 0: 0 ~ .2 ~ .4
FIG 2
Diamelro (nm)
FIG 3
40
[3]
 3.6 3.1 3.2 3.0 2.8 2.6 2.'1 2.2 2.0 1.8 1.6 1.41 1.2 1.0 0.6 0.6 004 0.2 0.0 --0.2 -0.4
"" '"
FIG 10
200 180 160 140 '"Q) 120
and
or
0 100
i 80
:: ¡;
60 40 20
O o
FIG 11
i ~
. ' 4
Diameter (nm)
 '' - JJ ~ ~~
[3]
3.0 0.8
FIG 12
'"4000
Q)
and
or
.Q
to 3000 ::;
2000 1000
2 3 "5 6 7 B 9 10 11 12 13 14 15
Dlameter (nm)
FIG 13
s. aureus E. coli CMI CMB CMI CMB
(mg / L) (mg / L) (mg / L) (mg / L)
BDCP078 64.00 128.00 128.00 128.00 BDCP079 8.00 8.00 16.00 16.00 BDCP080 8.00 16.00 32.00 32.00
FIG 20 Toxicity in CMSP
140 1 T
120 T ~ 100
~
..: - ¡.. ••.! ..! -1-1-1
~ 1 '"l · ~
.... 80 - ~ .I ~ i. ~
or '"
•
C. -.,
oc 60
"one
; g 40
 : g 1;
one-·-
:> 20
~ b
iO ~ ~ ~ 1 --E E E E
z Q x -E § § § § E E E E E § E E E § E E E §
..... W o, el el el o o, o, o, o, o, el o, o, o, o, el o, o, o, o, el ~ o,
or :::: t. :::: t. :::: t. :::: t. :::: t. :::: t. :: L :::: t. :::: t. :: L :: L :: L :::: t. :::: t. :::: t. :::: t. :::: t. :::: t. :::: t. :: L :::: t. :: L :: L :: L
or
..... ..... Q Q Q ..... ..... Q Q ..... Q Q Q ..... Q Q Q
in <=> <=> <=> ..., <=> ..., <=> Q <=> ..... <=> ..., ..., Q ..., Q
..... ..., Q ..... Q ..... Q ..... .....
~ ..... ..... ..... ..... ..... .....
OR
BDCP062 BDCP063 BDCP064 BDCP071 BDCP072 BDCP073
FIG 21
% Viability by MTT
.... ........ or: J
... in ce o
 "" ...
o o o o o o o o
""
% Viability by MTT
I
»
 NT ... ... ...
1 '.,) ~ = 1'.,) ~
in o
I o o o o o o o o
DMS010%
IDEXT
NT 0.01 J, lg / ml
DMS010% 0.05 Jglml
DEXT 0.1 J, lg / ml
[JI I
1: 1
0.5¡Jg / ml 0.01¡Ig / ml "U
n
or 1¡.g / ml
the [JI 0.05! .g / ml
one'.,)
10 ¡.g / ml 1: 1
d n ~
I x "U 0.1 ¡.Ig / ml _.X
50J, lg / ml I _. or (')
n .....
_.
I 0.5¡.1g / ml
100J, lglml
I a: c ..
. ",.:., ..: .. ~; .'- '..: t ..: .-.;.:> ~. ~ ..: ..: -: - Q)
0.01 J, lg / ml 1¡Ig / ml A)
Q. c ..
~ G)
. :.!; >. -: 0 -... ~ -,. ~
- ..j O, 05¡.glml <D (1)
N 0.01¡Ig / ml
N • :: r: s
0.1 J, lg / ml
[JI
- one
1: 1 tlI 0.05¡Ig / ml; :: l
n 0.5J, 1g / ml N e
"U I 3: n s:
or 1¡.g / ml -. "U 0.1! .G / ml
the OC"
C'"
W I ...
10¡.g / ml
I 0.5 l.1g / ml
I50¡.g / ml I
1¡Ig / ml
I
100¡.g / ml
I
0.01¡Ig / ml
Or, 01¡.g / ml
Or, 05¡.g / ml tlI 0.05¡Ig / ml
T
and
O, 1lJg / ml n
[JI • "O 0.1 ¡.Ig / ml
1: 1 or
O, 5lJg / ml ... ¡n "U O, 5¡.1g / ml
t.)
or 1lJg / ml
he
~ 1¡Ig / ml
10lJg / ml
I50lJg / ml II
100lJg / ml
I
% R5-HIV 1 inhibition in CMSP
........
IV ...CIlECor IV
ororororororor
NT
T20
100 ~ g / ml
BDCP062
'YOU
.l:>. <D G) N100 ~ g / ml BDCP063
.
100 ~ g / ml
BDCP064
100 ~ gfml
BDCP071
100 ~ g / ml
BDCP072
100 ~ g / ml
BDCP073

类似技术:

---

公开号 | 公开日 | 专利标题

---

ES2265291B1|2008-03-01|NEW CARBOSILAN DENDRIMEROS, ITS PREPARATION AND ITS USES.

---

ES2684090T3|2018-10-01|Biocidal formulations based on selenium and their methods of use

---

Lazniewska et al.2012|Dendrimers—revolutionary drugs for infectious diseases

---

WO2012037358A1|2012-03-22|Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents

---

JP5539733B2|2014-07-02|Self-assembling amphiphilic polymers as antiviral drugs

---

CA3007559A1|2009-05-14|Methods of preparing epoxide-functionalized polymers

---

WO2019104760A1|2019-06-06|Integrated nanosystem for liver-targeting co-delivery of gene/drug and preparation method therefor

---

Rabiee et al.2020|Carbosilane dendrimers: Drug and gene delivery applications

---

Mielanczyk et al.2016|In vitro evaluation of doxorubicin conjugates based on sugar core nonlinear polymethacrylates toward anticancer drug delivery

---

Li et al.2017|Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma

---

Wang et al.2019|Self-assembly of photosensitive and chemotherapeutic drugs for combined photodynamic-chemo cancer therapy with real-time tracing property

---

ES2609464B2|2018-06-01|Metal nanoparticles stabilized with carbosilane dendrons and their uses

---

Patra et al.2015|Simple synthesis of biocompatible biotinylated porous hexagonal ZnO nanodisc for targeted doxorubicin delivery against breast cancer cell: In vitro and in vivo cytotoxic potential

---

ES2444490A1|2014-02-25|Homo- and hetero-functionalised carbosilane dendritic compounds

---

US8765173B2|2014-07-01|Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

---

Mlynarczyk et al.2017|Dendrimer structure diversity and tailorability as a way to fight infectious diseases

---

US9198973B2|2015-12-01|PAMAM, spacer molecule and cafestol polymers

---

WO2020210367A1|2020-10-15|Ph-responsive silica metal organic framework nanoparticles for delivery of bio active molecules

---

ES2657282B1|2018-12-17|Carbonylane dendrones functionalized with fatty acids: micelle formation and uses

---

ES2374243B1|2012-12-26|NON-VIRAL VECTORS FOR GENE THERAPY.

---

EP2537880A2|2012-12-26|Carbosilane dendrimers and the use thereof as antiviral agents

---

ES2364264B2|2012-02-15|DENDRIMEROS CARBOSILANOS AND ITS USE AS ANTIVIRALS.

---

Jain2018|Dendrimers: Emerging anti-infective nanomedicines

---

ES2365685A1|2011-10-10|Carbosilan dendrimers with a polyphenolic nucleus and its use as antivirals. |

---

US20210070886A1|2021-03-11|Side chain modified peptoids useful as structure-stabilizing coatings for biomaterials

同族专利:

---

公开号 | 公开日

---

ES2609464B2|2018-06-01|

---

WO2017046433A1|2017-03-23|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

ES2830873A1|2019-12-04|2021-06-04|Univ Alcala Henares|MAGNETIC NANOPARTICLES STABILIZED WITH CARBOSILANE DENDRITIC SYSTEMS AND ITS USES |

法律状态:
2018-06-01| FG2A| Definitive protection|Ref document number: 2609464 Country of ref document: ES Kind code of ref document: B2 Effective date: 20180601 |

优先权:

---

申请号 | 申请日 | 专利标题

---

ES201500669A|ES2609464B2|2015-09-16|2015-09-16|Metal nanoparticles stabilized with carbosilane dendrons and their uses|ES201500669A| ES2609464B2|2015-09-16|2015-09-16|Metal nanoparticles stabilized with carbosilane dendrons and their uses|

---

PCT/ES2016/070642| WO2017046433A1|2015-09-16|2016-09-13|Metal nanoparticles stabilised with carbosilane dendrons and the uses thereof|